Cue Biopharma Presents CUE-401 Research Findings in Switzerland
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 09 2026
0mins
Should l Buy CUE?
Cue Biopharma announced that it will deliver a poster presentation on the company's lead asset, CUE-401, at the World Immune Regulation Meeting, WIRM, being held March 11-14, 2026 in Davos, Switzerland. The presentation will include new in vitro data that demonstrate the therapeutic potential of CUE-401 to restore immune balance for the treatment of autoimmune and inflammatory diseases. Title: CUE-401: A Novel Bifunctional TGF-beta/IL-2 Fusion Protein for the Treatment of Autoimmune and Inflammatory Diseases. In CD4+ T effector memory cells, CUE-401 showed TGF-beta-dependent suppression of proinflammatory cytokines, including Th1, Th2, and Th17 responses. In addition, the TGF-beta in CUE-401 prevented activated B cells from differentiating into plasma cells and limited antibody production. In natural killer cells, TGF-beta in CUE-401 counterbalanced the activating effects of interleukin-2, preventing proliferation and upregulation of proinflammatory cytokine production. Together, we believe these results demonstrate that CUE-401 has the potential to provide both short-term control of diverse inflammatory processes via TGF-beta, while also potentially providing durable long-term benefit through the induction and expansion of regulatory T cell responses
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CUE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CUE
About CUE
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cue Biopharma and Boehringer Ingelheim Announce Strategic Collaboration
- Strategic Collaboration: Cue Biopharma and Boehringer Ingelheim announced a strategic research collaboration and license agreement in April 2025 aimed at developing and commercializing Cue's CUE-501 product candidate for autoimmune diseases, which is expected to significantly enhance the company's market position in this sector.
- Milestone Payments: Cue Biopharma received an upfront payment of $12 million and is eligible for up to $345 million in research, development, and commercial milestone payments, providing robust funding support for the company's R&D efforts and aiding the clinical advancement of its CUE-401 asset.
- Stock Price Reaction: Cue Biopharma's shares surged 77% following the announcement, potentially marking the company's best trading day, reflecting strong market optimism about the collaboration, despite a 28% decline in stock price over the past 12 months.
- Retail Trader Sentiment: On Stocktwits, retail sentiment around CUE stock remained in the 'extremely bullish' territory with high message volume, indicating strong investor interest and confidence in the company's future developments.
See More
Cue Biopharma Secures $7.5 Million Milestone Payment
- Milestone Payment Confirmation: Cue Biopharma announced it will receive a $7.5 million preclinical milestone payment in May 2026, marking significant progress in its collaboration with Boehringer Ingelheim and showcasing the development potential of CUE-501.
- Collaboration Achievements: This payment follows Boehringer's selection and approval of the first compound for lead optimization, indicating important advancements in CUE-501's targeted depletion of specific B cells, aimed at addressing autoimmune and inflammatory diseases.
- Future Potential: Under the collaboration agreement, Cue Biopharma is eligible for up to $337.5 million in additional milestone payments and royalties on future net sales, providing robust financial support for the company's future growth.
- Market Reaction Volatility: Despite Cue Biopharma's stock trading between $0.16 and $1.03 over the past year, it closed at $0.27, with a pre-market drop of 18.85%, reflecting cautious market sentiment regarding the company's outlook.
See More
CUE BIOPHARMA INC ANTICIPATES $7.5 MILLION PAYMENT IN MAY 2026
- Payment Expectation: Cue Biopharma anticipates receiving a payment of $7.5 million.
- Timeline for Payment: The expected payment is scheduled for May 2026.
See More
Cue Biopharma CEO Resignation Leads to 8% Stock Drop
- Executive Departure: Cue Biopharma's CEO Usman Azam resigned effective March 26, causing an 8% drop in stock price during extended trading hours, indicating market concerns over leadership instability that may affect investor confidence.
- Interim Leadership: Lucinda Warden has been appointed as interim CEO; she has served as the company's CFO since February 2026 and previously as CBO from September 2024 to February 2026, suggesting continuity in leadership but raising questions about future strategic direction.
- Clinical Trial Advancement: Cue Biopharma aims to progress its lead asset CUE-401 into clinical trials in the second half of this year, with preclinical studies showing no adverse events, which could provide new growth opportunities in the treatment of autoimmune and inflammatory diseases if successful.
- Collaboration Agreement: The company entered into a collaboration and licensing agreement with ImmunoScape to advance a novel cell therapy approach, combining both companies' technologies, which could enhance Cue's competitiveness in tumor treatment and expand its product offerings.
See More
CUE Stock Declines Following CEO's Departure After Only Six Months
Leadership Change: Cue Biopharma's shares dropped 8% after the announcement that CEO Usman Azam stepped down, effective March 26, after only six months in the role. Lucinda Warden has been appointed as the interim president and CEO.
Clinical Trials Progress: The company is focusing on advancing its lead investigational drug, CUE-401, into clinical trials in the second half of the year, targeting autoimmune and inflammatory diseases.
Collaboration Agreement: Cue Biopharma entered a collaboration and license agreement with ImmunoScape to develop a novel in vivo approach for cell therapy aimed at treating solid tumors.
Stock Performance: Cue Biopharma's stock has seen a significant decline of 76% over the past 12 months, with retail sentiment remaining bearish despite some recovery in messaging volume.
See More
Cue Biopharma Appoints New Interim CEO
- Executive Change: Cue Biopharma announced the appointment of Lucinda Warren as interim President and CEO, succeeding Usman Azam who stepped down effective March 26, 2026, indicating a significant leadership shift that may impact the company's strategic direction.
- Extensive Experience: Warren brings over 30 years of experience in the pharmaceutical and biotech sectors, having held senior roles at Johnson & Johnson, and this appointment aims to leverage her expertise to drive company growth, particularly in the current market environment.
- Market Reaction: Following the announcement, Cue Biopharma's shares fell by 4.58%, reflecting investor unease regarding the executive transition, which could affect the company's short-term market performance and investor confidence.
- Board Role: Warren currently serves as chairman of the board for International School Services, and this dual role may provide her with broader perspectives and resources to help the company navigate through complex market challenges.
See More
Cue Biopharma and Boehringer Ingelheim Announce Strategic Collaboration
- Strategic Collaboration: Cue Biopharma and Boehringer Ingelheim announced a strategic research collaboration and license agreement in April 2025 aimed at developing and commercializing Cue's CUE-501 product candidate for autoimmune diseases, which is expected to significantly enhance the company's market position in this sector.
- Milestone Payments: Cue Biopharma received an upfront payment of $12 million and is eligible for up to $345 million in research, development, and commercial milestone payments, providing robust funding support for the company's R&D efforts and aiding the clinical advancement of its CUE-401 asset.
- Stock Price Reaction: Cue Biopharma's shares surged 77% following the announcement, potentially marking the company's best trading day, reflecting strong market optimism about the collaboration, despite a 28% decline in stock price over the past 12 months.
- Retail Trader Sentiment: On Stocktwits, retail sentiment around CUE stock remained in the 'extremely bullish' territory with high message volume, indicating strong investor interest and confidence in the company's future developments.
See More
Cue Biopharma Secures $7.5 Million Milestone Payment
- Milestone Payment Confirmation: Cue Biopharma announced it will receive a $7.5 million preclinical milestone payment in May 2026, marking significant progress in its collaboration with Boehringer Ingelheim and showcasing the development potential of CUE-501.
- Collaboration Achievements: This payment follows Boehringer's selection and approval of the first compound for lead optimization, indicating important advancements in CUE-501's targeted depletion of specific B cells, aimed at addressing autoimmune and inflammatory diseases.
- Future Potential: Under the collaboration agreement, Cue Biopharma is eligible for up to $337.5 million in additional milestone payments and royalties on future net sales, providing robust financial support for the company's future growth.
- Market Reaction Volatility: Despite Cue Biopharma's stock trading between $0.16 and $1.03 over the past year, it closed at $0.27, with a pre-market drop of 18.85%, reflecting cautious market sentiment regarding the company's outlook.
See More
CUE BIOPHARMA INC ANTICIPATES $7.5 MILLION PAYMENT IN MAY 2026
- Payment Expectation: Cue Biopharma anticipates receiving a payment of $7.5 million.
- Timeline for Payment: The expected payment is scheduled for May 2026.
See More
Cue Biopharma CEO Resignation Leads to 8% Stock Drop
- Executive Departure: Cue Biopharma's CEO Usman Azam resigned effective March 26, causing an 8% drop in stock price during extended trading hours, indicating market concerns over leadership instability that may affect investor confidence.
- Interim Leadership: Lucinda Warden has been appointed as interim CEO; she has served as the company's CFO since February 2026 and previously as CBO from September 2024 to February 2026, suggesting continuity in leadership but raising questions about future strategic direction.
- Clinical Trial Advancement: Cue Biopharma aims to progress its lead asset CUE-401 into clinical trials in the second half of this year, with preclinical studies showing no adverse events, which could provide new growth opportunities in the treatment of autoimmune and inflammatory diseases if successful.
- Collaboration Agreement: The company entered into a collaboration and licensing agreement with ImmunoScape to advance a novel cell therapy approach, combining both companies' technologies, which could enhance Cue's competitiveness in tumor treatment and expand its product offerings.
See More
CUE Stock Declines Following CEO's Departure After Only Six Months
Leadership Change: Cue Biopharma's shares dropped 8% after the announcement that CEO Usman Azam stepped down, effective March 26, after only six months in the role. Lucinda Warden has been appointed as the interim president and CEO.
Clinical Trials Progress: The company is focusing on advancing its lead investigational drug, CUE-401, into clinical trials in the second half of the year, targeting autoimmune and inflammatory diseases.
Collaboration Agreement: Cue Biopharma entered a collaboration and license agreement with ImmunoScape to develop a novel in vivo approach for cell therapy aimed at treating solid tumors.
Stock Performance: Cue Biopharma's stock has seen a significant decline of 76% over the past 12 months, with retail sentiment remaining bearish despite some recovery in messaging volume.
See More
Cue Biopharma Appoints New Interim CEO
- Executive Change: Cue Biopharma announced the appointment of Lucinda Warren as interim President and CEO, succeeding Usman Azam who stepped down effective March 26, 2026, indicating a significant leadership shift that may impact the company's strategic direction.
- Extensive Experience: Warren brings over 30 years of experience in the pharmaceutical and biotech sectors, having held senior roles at Johnson & Johnson, and this appointment aims to leverage her expertise to drive company growth, particularly in the current market environment.
- Market Reaction: Following the announcement, Cue Biopharma's shares fell by 4.58%, reflecting investor unease regarding the executive transition, which could affect the company's short-term market performance and investor confidence.
- Board Role: Warren currently serves as chairman of the board for International School Services, and this dual role may provide her with broader perspectives and resources to help the company navigate through complex market challenges.
See More
